TRUVADA | Annual Sales Report | Pharmacompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

TRUVADA
Annual Reports

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

Contact Supplier

pharmacompass-1-m-2025-11-03

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

pharmacompass-2-m-2025-11-03

TRUVADA

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

40 API Suppliers, 16 USDMF, 2 JDMF, 12 EU WC, 6 KDMF, 20 NDC API, 17 Listed Suppliers, $ API Reference Price

40 API Suppliers
16 USDMF
2 JDMF
12 EU WC
6 KDMF
20 NDC API
17 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

115 Drugs in Development

115 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

229 FDF Dossiers, 60 FDA Orange Book, 81 Europe, 22 Canada, 53 South Africa, 13 Listed Dossiers

229 FDF Dossiers
60 FDA Orange Book
81 Europe
22 Canada
53 South Africa
13 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 200MG;EQ 25MG BASE;300MG, TABLET;ORAL - 150MG;150MG;200MG;300MG, TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE, TABLET;ORAL - 120MG;EQ 15MG BASE, TABLET;ORAL - 200MG;EQ 25MG BASE, TABLET;ORAL - 200MG;EQ 25MG BASE;EQ 25MG BASE, TABLET;ORAL - EQ 30MG BASE;120MG;EQ 15MG BASE, TABLET;ORAL - EQ 50MG BASE;200MG;EQ 25MG BASE, CAPSULE;ORAL - 200MG, TABLET;ORAL - 100MG;150MG, TABLET;ORAL - 133MG;200MG, TABLET;ORAL - 167MG;250MG, TABLET;ORAL - 200MG;300MG

TABLET;ORAL - 200MG;EQ 25MG BASE;300MG
TABLET;ORAL - 150MG;150MG;200MG;300MG
TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE
TABLET;ORAL - 120MG;EQ 15MG BASE
TABLET;ORAL - 200MG;EQ 25MG BASE
TABLET;ORAL - 200MG;EQ 25MG BASE;EQ 25MG BASE
TABLET;ORAL - EQ 30MG BASE;120MG;EQ 15MG BASE
TABLET;ORAL - EQ 50MG BASE;200MG;EQ 25MG BASE
CAPSULE;ORAL - 200MG
TABLET;ORAL - 100MG;150MG
TABLET;ORAL - 133MG;200MG
TABLET;ORAL - 167MG;250MG
TABLET;ORAL - 200MG;300MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 4 SPI Pharma, 10 DKSH, 1 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Kirsch Pharma, 4 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 26 BASF, 10 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 2 Finar, 8 Gangwal Chemicals, 5 Ideal Cures, 3 Ingredion Pharma Solutions, 21 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 2 Pharmatrans-Sanaq, 6 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 16 Roquette, 9 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

54 Fillers, Diluents & Binders, 48 Coating Systems & Additives, 27 Controlled & Modified Release, 25 Thickeners and Stabilizers, 25 Granulation, 22 Direct Compression, 19 Disintegrants & Superdisintegrants, 17 Topical, 17 Solubilizers, 15 Lubricants & Glidants, 11 Parenteral, 11 Film Formers & Plasticizers, 11 Taste Masking, 10 Co-Processed Excipients, 9 Empty Capsules, 8 Chewable & Orodispersible Aids, 6 Emulsifying Agents, 5 Rheology Modifiers, 5 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

54 Fillers, Diluents & Binders
48 Coating Systems & Additives
27 Controlled & Modified Release
25 Thickeners and Stabilizers
25 Granulation
22 Direct Compression
19 Disintegrants & Superdisintegrants
17 Topical
17 Solubilizers
15 Lubricants & Glidants
11 Parenteral
11 Film Formers & Plasticizers
11 Taste Masking
10 Co-Processed Excipients
9 Empty Capsules
8 Chewable & Orodispersible Aids
6 Emulsifying Agents
5 Rheology Modifiers
5 API Stability Enhancers
5 Coloring Agents
4 Vegetarian Capsules
4 Surfactant & Foaming Agents

DIGITAL CONTENT

3 Data Compilation #PharmaFlow, 2 Stock Recap #PipelineProspector, 196 News #PharmaBuzz

3 Data Compilation #PharmaFlow
2 Stock Recap #PipelineProspector
196 News #PharmaBuzz

GLOBAL SALES INFORMATION

24 US Medicaid Prescriptions, 11 Regulatory FDF Prices, 120 Annual Reports

24 US Medicaid Prescriptions
11 Regulatory FDF Prices
120 Annual Reports

MARKET PLACE

8 APIs, 9 FDF Dossiers

8 APIs
9 FDF Dossiers

PATENTS & EXCLUSIVITIES

96 US Patents, 9 US Exclusivities, 54 Health Canada Patents

96 US Patents
9 US Exclusivities
54 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 USP, 6 Others

4 USP
6 Others

$ API Ref.Price (USD/KG) : 319 Xls

Filters

Reset all filters

Filters

FILTER :

filter Product Reset all filters

120 All

01 5Atripla

02 12Biktarvy

03 1Complera

04 1Complera /Eviplera

05 8Complera/Eviplera

06 14Descovy

07 20Genvoya

08 14Odefsey

09 5Prezista/Prezcobix/Rezolsta/Symtuza

10 7Revenue share - Symtuza

11 15Stribild

12 9Symtuza

13 9Truvada

List of Suppliers

Product Main Page

01

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Johnson & Johnson

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Brand Name : Atripla

AAPS

Not Confirmed

Brand Name : Atripla

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 349

2019 Revenue in Millions : 600

Growth (%) : -42

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Brand Name : Descovy

AAPS

Not Confirmed

Brand Name : Descovy

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 1,861

2019 Revenue in Millions : 1,500

Growth (%) : 24

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Brand Name : Odefsey

AAPS

Not Confirmed

Brand Name : Odefsey

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 1,672

2019 Revenue in Millions : 1,655

Growth (%) : 1

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Brand Name : Stribild

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Stribild

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 196

2019 Revenue in Millions : 369

Growth (%) : -47

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Brand Name : Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Symtuza

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 488

2019 Revenue in Millions : 379

Growth (%) : 29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Brand Name : Genvoya

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Genvoya

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 3,338

2019 Revenue in Millions : 3,931

Growth (%) : -15

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Brand Name : Symtuza

Bictegravir, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Symtuza

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Bictegravir, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 488

2019 Revenue in Millions : 379

Growth (%) : 29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Brand Name : Genvoya

Bictegravir, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Genvoya

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Bictegravir, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 3,338

2019 Revenue in Millions : 3,931

Growth (%) : -15

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Brand Name : Biktarvy

Bictegravir, Emtricitabine, Tenofovir Alafenamide

AAPS

Not Confirmed

Brand Name : Biktarvy

AAPS

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Bictegravir, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 7,259

2019 Revenue in Millions : 4,738

Growth (%) : 53

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!